Trial Profile
Bioequivalence study of rimegepant Zydis ODT formulation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Oct 2019
Price :
$35
*
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- Sponsors Biohaven Pharmaceutical Holding Company
- 06 Sep 2018 According to a Biohaven Pharmaceutical Holding Company media release, data from this trial will be presented at the 17th Biennial Migraine Trust International Symposium (MTIS).
- 05 Jun 2018 According to a Biohaven Pharmaceutical Holding Company media release, expanded data will be presented at the American Headache Society (AHS) 60th Annual Scientific Meeting 2018.
- 08 Mar 2018 New trial record